BNP Paribas Financial Markets Portfolio holdings
BNP Paribas Financial Markets, a core component of BNP Paribas’s Corporate & Institutional Banking (CIB) division, is a global leader in trading and market-making, headquartered in Paris with major hubs in London, New York, Hong Kong, and Singapore. Specializing in derivatives across all asset classes—equities, fixed income, commodities, and foreign exchange—it provides innovative investment, hedging, and financing solutions to corporate clients, institutional investors, and financial institutions worldwide. Known for its advanced technological infrastructure and quantitative expertise, the division excels in structured financing and electronic trading, supported by a robust balance sheet and a diversified business model that proved resilient during the 2008 financial crisis. With a presence in over 50 countries and a client base exceeding 13,000, BNP Paribas Financial Markets drives market liquidity and offers cutting-edge research and execution services, reinforcing its position as a top-tier player in global capital markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$140M |
| 2 |
iShares US Financials ETF
IYF
|
+$119M |
| 3 |
AGN
Allergan plc
AGN
|
+$100M |
| 4 |
Charter Communications
CHTR
|
+$95.1M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$82.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.2B |
| 2 |
State Street SPDR S&P Biotech ETF
XBI
|
+$909M |
| 3 |
Invesco QQQ Trust
QQQ
|
+$623M |
| 4 |
Apple
AAPL
|
+$389M |
| 5 |
iShares Russell 2000 ETF
IWM
|
+$369M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 7.73% |
| 2 | Financials | 5.47% |
| 3 | Healthcare | 4.96% |
| 4 | Consumer Discretionary | 4.64% |
| 5 | Industrials | 3.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3776
iShares US Healthcare ETF
IYH
$3.78B
| $28.5K | ﹤0.01% |
660
-2,135
| -76% | -$86.2K |
|
3777
BeyondSpring
BYSI
$30.5M
| $28.2K | ﹤0.01% |
1,822
+461
| +34% | +$6.84K |
|
3778
PUT
ServiceNow
NOW
$129B
| $28.2K | ﹤0.01% |
5
| – | – |
|
3779
Acacia Research
ACTG
$455M
| $28.2K | ﹤0.01% |
10,596
+2,788
| +36% | +$7.64K |
|
|
BFYT
3780
DELISTED
Benefytt Technologies, Inc. Class A Common Stock
BFYT
| $28.2K | ﹤0.01% |
1,460
-254
| -15% | -$5.74K |
|
3781
First Guaranty Bancshares
FGBI
$139M
| $28.1K | ﹤0.01% |
1,420
+465
| +49% | +$8.3K |
|
|
REV
3782
DELISTED
Revlon, Inc.
REV
| $28K | ﹤0.01% |
1,308
-100
| -7% | -$2.41K |
|
3783
Altisource Portfolio Solutions
ASPS
$64.5M
| $27.9K | ﹤0.01% |
181
| – | – |
|
|
NGD
3784
DELISTED
New Gold Inc
NGD
| $27.9K | ﹤0.01% |
31,680
| – | – |
|
|
SYRS
3785
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $27.7K | ﹤0.01% |
401
-48
| -11% | -$2.91K |
|
3786
Twin Disc
TWIN
$355M
| $27.7K | ﹤0.01% |
2,512
+898
| +56% | +$9.39K |
|
|
ENZ
3787
DELISTED
Enzo Biochem, Inc.
ENZ
| $27.5K | ﹤0.01% |
10,450
+3,306
| +46% | +$9.88K |
|
|
ITI
3788
DELISTED
Iteris, Inc.
ITI
| $27.5K | ﹤0.01% |
5,507
-186
| -3% | -$947 |
|
3789
Scholar Rock
SRRK
$6.55B
| $27.4K | ﹤0.01% |
2,080
-361
| -15% | -$3.46K |
|
3790
Sasol
SSL
$7.36B
| $27.4K | ﹤0.01% |
1,267
+313
| +33% | +$5.99K |
|
|
CURO
3791
DELISTED
CURO Group Holdings Corp.
CURO
| $27.2K | ﹤0.01% |
2,235
+24
| +1% | +$321 |
|
3792
Arq
ARQ
$100M
| $27K | ﹤0.01% |
2,568
-305
| -11% | -$3.65K |
|
|
USX
3793
DELISTED
U.S. Xpress Enterprises, Inc. Class A Common Stock
USX
| $26.9K | ﹤0.01% |
5,354
+1,723
| +47% | +$8.39K |
|
|
OPTN
3794
DELISTED
OptiNose
OPTN
| $26.9K | ﹤0.01% |
195
-30
| -13% | -$3.89K |
|
|
GFN
3795
DELISTED
General Finance Corporation
GFN
| $26.9K | ﹤0.01% |
2,429
+483
| +25% | +$4.76K |
|
|
FTR
3796
DELISTED
Frontier Communications Corp.
FTR
| $26.9K | ﹤0.01% |
30,202
+11,181
| +59% | +$9.11K |
|
3797
Spero Therapeutics
SPRO
$68.9M
| $26.8K | ﹤0.01% |
2,792
+1,353
| +94% | +$14.6K |
|
3798
Sutro Biopharma
STRO
$353M
| $26.7K | ﹤0.01% |
243
+116
| +91% | +$12K |
|
3799
Evolus
EOLS
$536M
| $26.7K | ﹤0.01% |
2,193
+69
| +3% | +$973 |
|
3800
Replimune Group
REPL
$1.28B
| $26.7K | ﹤0.01% |
1,859
-55
| -3% | -$793 |
|
Similar funds
BNP Paribas Financial Markets's Q4 2019 Portfolio in Review
As of Q4 2019, BNP Paribas Financial Markets held 4,613 positions worth $54.9B, down 2.5% from $56.3B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
BNP Paribas Financial Markets withdrew a net $10.1B in Q4 2019, closing 185 positions and reducing 1,420 holdings. Its most notable exit was Celgene Corp, an estimated $56.8M position sold in full.
By sector, the portfolio is most concentrated in Technology at 7.7% of assets, down from 8.3% a quarter earlier, followed by Financials and Healthcare.
Against the trend, BNP Paribas Financial Markets opened a new position in iShares US Financials ETF worth $124M.
- BNP Paribas Financial Markets's largest Q4 2019 buy was iShares US Financials ETF: 1,800,000 shares worth $124M.
- BNP Paribas Financial Markets added most to Bristol-Myers Squibb in Q4 2019, an estimated $140M increase.
- BNP Paribas Financial Markets's biggest Q4 2019 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $1.2B.
- BNP Paribas Financial Markets fully exited Celgene Corp in Q4 2019, selling an estimated $56.8M.
- BNP Paribas Financial Markets's ten largest holdings make up 16% of its $54.9B portfolio in Q4 2019.
- BNP Paribas Financial Markets opened 106 new positions and closed 185 in Q4 2019.
- BNP Paribas Financial Markets's portfolio value fell 2.5% quarter-over-quarter to $54.9B.
Based on BNP Paribas Financial Markets's 13F filing for Q4 2019, filed 12 Feb 2020.